E
Enanta Pharmaceuticals, Inc. (ENTA)
NMS – Real vaqt narxi. Valyuta: USD
13.50
-0.02 (-0.15%)
Yopilishda: Aug 12, 2026, 4:00 PM EDT
13.50
0.00 (0.00%)
Bozordan keyin: Aug 12, 2026, 4:10 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
13.50
-0.02 (-0.15%)
Yopilishda: Aug 12, 2026, 4:00 PM EDT
13.50
0.00 (0.00%)
Bozordan keyin: Aug 12, 2026, 4:10 PM EDT
Enanta Pharmaceuticals, Inc., biotexnologiya kompaniyasi, virusologiya va immunologiya ko'rsatkichlari uchun kichik molekulyar dori vositalarini ishlab chiqadi va rivojlantiradi. Kompaniyaning mahsulot quvurlari quyidagilarni o'z ichiga oladi: B gepatit virusi yoki HBV bilan surunkali infektsiyani davolash uchun 1b faza klinik rivojlanishida bo'lgan EDP-514; respirator-sintsial virusni davolash uchun II faza klinik rivojlanishida bo'lgan zelicapavir va EDP-323; inson koronaviruslarini davolash uchun II faza klinik rivojlanishida bo'lgan EDP-235; surunkali spontan ürtiker (CSU) uchun EDP-978; S gepatit virusi yoki HCV bilan surunkali infektsiyani davolash uchun antiviral proteaz inhibitorlari bo'lgan Glecaprevir; va atopik dermatitni davolash uchun EPS-3903. Kompaniya paritaprevir va glecaprevirni o'z ichiga olgan HCV NS3 va NS3/4A proteaz inhibitor birikmalarini ishlab chiqish, ishlab chiqarish va tijoratlashtirish uchun Abbott Laboratories bilan hamkorlikdagi rivojlanish va litsenziya shartnomasiga ega. Kompaniya 1995 yilda ro'yxatga olingan va Massachusets shtatining Uoterdaun shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jay R. Luly Ph.D. | President, CEO & Director |
| Dr. Scott T. Rottinghaus M.D. | Chief Medical Officer |
| Dr. Yat Sun Or Ph.D. | Chief Scientific Officer |
| Mr. Brendan Luu | Chief Business Officer |
| Mr. Harry R. Trout III | VP of Finance & Interim Principal Financial Officer |
| Mr. Matthew P. Kowalsky J.D. | Chief Legal Officer & Corporate Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-08-12 | 10-Q | enta-20260630.htm |
| 2026-08-10 | 8-K | enta-20260810.htm |
| 2026-07-02 | 8-K | d123412d8k.htm |
| 2026-06-23 | 8-K | d133783d8k.htm |
| 2026-06-18 | 8-K | d159604d8k.htm |
| 2026-05-13 | S-8 | d53800ds8.htm |
| 2026-05-13 | 10-Q | enta-20260331.htm |
| 2026-05-11 | 8-K | enta-20260511.htm |
| 2026-03-26 | 8-K | enta-20260320.htm |
| 2026-03-12 | 8-K | enta-20260311.htm |
| Mr. Nathaniel S. Gardiner J.D. | Consultant |
| Ms. Jennifer Viera | Executive Director of Investor Relations & Corporate Communications |
| Ms. Kathleen S. Capps CPA | Executive Director of Accounting, Controller & Interim Principal Accounting Officer |
| Ms. Tara Lynn Kieffer Ph.D. | Chief Product Strategy Officer |